Novo Nordisk has been looking to diversify its lineup in recent years, and is developing medicines in other fields. The ...

The FDA’s recent approval of OZEMPIC highlights the expanding use of GLP-1 drugs beyond diabetes and weight management. Novo Nordisk’s blockbuster medication has gained another label expansion, now ...

Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO ...

Novo Nordisk (NVO) stock took a hit this week, after a Super Bowl ad highlighted a growing challenge to the company’s ...

American demand for weight-loss drugs is supercharging Denmark’s economy and transforming a small Danish community into an ...

The manufacturer of the weight loss jab Wegovy has been reprimanded for allegedly failing to disclose or accurately report ...

Ozempic is synonymous with weight loss for many people. Doctors explain benefits and risks of semaglutide and other GLP-1 ...

Ozempic may also help people drink less alcohol. Primary care doctors are concerned about patients accessing GLP-1s through ...

Det vrimler med russiske Ozempic-kopier, efter at Novo Nordisk trak produktet ud af landet. Men det har ingen patentpenge ...

Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Den amerikanske medicinalindustri skal mødes med præsident Donald Trump i Det Hvide Hus. Industrien vil forsøge at få Trump til at lempe prispresset på dyr medicin som Wegovy og Ozempic. Spørgsmålet ...